SAN FRANCISCO, Aug.

BRIDGEWATER, N.J., July 29 /PRNewswire-FirstCall/ -- Change Change Change at Change at on a constant on a constant Q2 reported exchange reported exchange 2009 basis rates H1 2009 basis rates ------- --------- -------- ------- ------- ------- Net euro euro sales 7,438m +11.2% +6.5% 14,545m +6.7% +3.1% Adjusted net income excluding selected euro euro items 2,268m +29.4% +17.2% 4,446m +22.3% +12.8% Adjusted EPS excluding selected euro euro items 1.74 +29.9% +17.2% 3.41 +23.1% +13.4% In order to facilitate an understandin

Exelixis, a development-stage biotechnology company, has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to discover novel therapies targeted against the liver X receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.

Exelixis, Inc.

Exelixis, a development-stage biotechnology company, has reported positive interim data from a Phase I dose-escalation trial of XL765, a small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.